垂体催乳素瘤的病因及发病机制的实验研究

应用在同一只雄性ＳＤ大鼠中,保留原位垂体并在肾囊内植入一异体垂体,同时背部埋植装有１７－β－雌二醇（１７－β－ｅｓｔｒａｄｉｏｌ,Ｅ２）的药泵,经Ｅ２在体作用６０￣１２０天后,其原位垂体和异体移植入肾囊的垂体同时形成２垂体催乳素（ｐｒｏｌａｃｔｉｎ,ＰＲＬ）瘤的动物模型,研究ＰＲＬ瘤的发病机制。结果表明,Ｅ２长期作用可诱发原位垂体和远离下丘脑的移植垂体同时形成ＰＲＬ瘤,并伴高ＰＲＬ血症和ＰＲＬ基因     

雌激素诱发大鼠原位与移植垂体催乳素瘤中催乳素基因与TGFα和TGFβ1基因的表达

利用本实验室建立的17β雌二醇(17βestradiol,E2)诱致SpragueDawley(SD)大鼠原位垂体和异体移植于肾囊的垂体同时形成催乳素(prolactin,PRL)瘤的动物模型,采用Northern印迹杂交方法,我们观察了E2长期作用(120d)后诱发的原位与移植垂体PRL瘤中PRL基因和两种转化生长因子(transforminggrowthfactor,TGF)TGFα和TGFβ1基因表达水平的改变。结果表明:在E2长期作用后,原位垂体与异体移植于肾囊,从而远离下丘脑的垂体均可形成垂体PRL瘤;原位与移植垂体PRL瘤中均表现PRL基因的高表达,但移植瘤中的PRL基因表达水平低于原位垂体瘤;此外,仅在原位垂体PRL瘤中发现上述两种转化生长因子呈较高水平的表达,移植垂体PRL瘤与正常垂体中均检测不到这两种转化生长因子的表达。上述结果提示,TGFα和TGFβ1可能涉及E2诱发的原位垂体PRL瘤形成;E2诱发原位与移植垂体形成PRL瘤的机制可能不尽相同     

TGF—β家族的细胞信号转导

转化生长因子β（ＴＧＦ－β）家族成员与各自的膜受体结合后,使通路限制性（ｐａｔｈｗａｙ－ｒｅｓｔｒｉｃｔｅｄ）ＳＭＡＤｓ磷酸化,后者再与Ｓｍａｄ４形成杂聚体并转位至细胞核,调节一些基因的转录而产生生物学效应。抑制性ＳＭＡＤｓ可阻断通路限制性ＳＭＡＤｓ的磷酸化。     

GRP和VIP对E2诱致的垂体催乳素（PRL）瘤细胞PRL基因转录的影响

实验应用雄性ＳＤ大鼠,皮下埋植内置１０ｍｇ雌二醇硅胶管３个月致体催乳素瘤后,取ＰＲＬ瘤细胞进行外原代培养,并应用原位杂交方法,研究不同剂量的胃泌素释放肽（ｇａｓｔｒｉｎ－ｒｅｌｅａｉｎｇｐｅｐｔｉｄｅ,ＧＲＰ）和血活性肠肽（ｖａｓｏａｃｔｉｖｅｉｎｔｅｓｔｉｎａｌｐｏｌｙｐｅｐｔｉｄｅ,ＶＩＰ）以及Ｅ２对 离体培养的垂体ＰＲＬ瘤细胞ＰＲＬ基因转录的,下,ＧＲＰ,ＶＩＰ分别与ＰＲＬ瘤细胞孵育２４ｈ后     

外源TGF—β1基因在小鼠ES细胞中的表达及其对细胞分化的影响

本文利用逆转录病毒载体Ｄｏｌ,在其ＢａｍＨＩ酶切位点插入猪ＴＧＦ－β１ １．７ｋｂｃＫＮＡ,构建成表达质粒,并用磷酸钙沉淀法将该质粒ＤＮＡ转染到小鼠ＥＳ－５细胞,经Ｇ４１８筛选获得抗Ｇ４１８的ＥＳ－５细胞克隆（ＥＳ－Ｔ）,经ＲＮＡ点杂交,Ｎｏｒｔｈｅｒｎ印迹杂交证明有６个细胞克隆能表达外源猪ＴＧＦ－β１的ｍＲＮＡ,其中两个杂交信号较强的克隆进一步用Ｓｏｕｔｈｅｒｎ印迹杂交,也证明猪ＴＧＦ－μ     

ES细胞分化为血管样结构的机理探讨—TGF—β1在血管形成中的作用

本文利用小鼠ＥＳ细胞的拟胚一培养和三维胶原蛋白培养系统研究了外源ｒｈＴＧＦ－β１对ＥＳ细胞分化为血管样样结构的影响。结果发现,远方介培养中添加外源ｒｈＴＧＦ－β１或细胞经基因转染面有过度表达的ＴＧＦ－β１的ＥＳ－Ｔ６细胞分化为血管样结构的频率明显地受到抑制,相似于其亲本ＥＳ－５细胞的分化水平。在Ｉ型胶原三维培养系统中的单层ＥＳ－５细胞培液中添加ｒｈＴＧＦ－β１时,明显地促进ＥＳ－５细胞形成血管样结     

肽类生长因子对抗癌基因的诱导作用

观察了肽类生长因子对２ＢＳ细胞中抗癌基因表达的影响。结果表明,ＥＧＦ或ＦＧＦ均可明显诱导２ＢＳ细胞中Ｒｂ基因的表达,其幅度分别为３０５％、２４３％;ＥＧＦ也可诱导２ＢＳ细胞中ＴＧＦβ１基因表达增加３０－５０％,但ＦＧＦ对ＴＧＦβ１的表达无明显影响;ＥＧＦ或ＦＧＦ对ｐ５３基因的表达均无明显诱导作用。上述结果为生长因子作用机制研究及生长因子与抗癌基因的关系提供了新的线索。     

TGF—β家族信号的细胞内传导蛋白：MAD蛋白家族

ＳＭＡＤｓ是新近发现的参与ＴＧＦ－β超家族的信号在细胞内声望地的一族蛋白,包括８个成员,分别称ＳＭＡＤ１－８。ＳＭＡＤ１、２、３、５和８属于一类,它们被ＴＧＦ－β的受体或ＢＭＰ的受体激活而磷酸化,称为受体调节ＳＭＡＤ,传导下ＴＧＦ－β或ＢＭＰ的信号。ＳＭＡＤ６和７属于另一类,它们抑制制受体调节ＳＭＡＤ的信号传导。ＳＭＡＤ４是第三类,它是受体调节ＳＭＡＤ传导信号的伴侣。受体调节ＳＭＡＤ传导信号必须先     

大鼠催乳素基因真核细胞可表达性质粒的构建及应用研究

７３５ｂｐ的ＰＲＬｃＤＮＡ片段从质粒ＰＲＬ－ＳＰ６５＃１中回收后,用粘性末端连接法将其重组到真核表达载体ｐｃＤＮＡ３上,筛选出正向连接重组体ｐｃＤＮＡ３－ＰＲＬＳ和反向连接重组体ｐｃＤＮＡ３－ＰＲＬＡＳ。将重组体ｐｃＤＮＡ３－ＰＲＬｓ和空载体ｐｃＤＮＡ３分别转入ＮＩＨ３Ｔ３细胞系,用Ｇ４１８筛选出阳性细胞后与未转染的ＮＩＨ３Ｔ３细胞在加Ｅ２和不加Ｅ２的情况下,用原位杂交的方法,分别用ＰＲＬｃＤＮＡ探针和原癌基因ｃ－Ｈ－ｒａｓｃＤＮＡ探针进行检测,未转染的ＮＩＨ３Ｔ３细胞在加Ｅ２和不加Ｅ２时都几乎无催乳素基因的表达,同样,转入空载体的ＮＩＨ３Ｔ３细胞也无ＰＲＬ的表达,而转入重组体ｐｃＤＮＡ３－ＰＲＬＳ的ＮＩＨ３Ｔ３细胞则有大量的ＰＲＬ基因的表达,与对照组相比有显著差异（Ｐ＜０．０１）。正常和转入空载体的ＮＩＨ３Ｔ３细胞有一定程度的原癌基因ｃ－Ｈ－ｒａｓ的表达,当分别加入Ｅ２和转入重组体ｐｃＤＮＡ３－ＰＲＬＳ后,ＮＩＨ３Ｔ３细胞中的ｃ－Ｈ－ｒａｓ基因表达水平都显著升高（Ｐ＜０．０５）。     

TGF—β的结构,受体及信号转导

转化生长因子β（ＴＧＦ－β）是一种多功能细胞因子。人、鼠等哺乳动物的ＴＧＦ－β已克隆出β１、β２、β３３种亚单位。活性ＴＧＦ－β是分子量的２５ｋＤ的同源二聚体,每个单体由１１２个氨基酸组成。ＴＧＦ－β受体有ＴβＲⅠ￣Ⅴ、Ｅｎｄｏｇｌｉｎ等。其中ＴβＲⅠ、ＴβＲⅡ属丝氨酸／苏氨酸激酶家族,在ＴＧＦ－β信号转导中起主导作用。ＴＧＦ－β与ＴβＲⅡ结合后,再结合ＴβＲⅠ,然后ＴβＲⅡ磷酸化ＴβＲⅠ,后作     

Pituitary prolactin-secreting tumor formation: recent developments

Prolactinoma is the most common type of primary pituitary tumors. It occurs more frequently in women than in men. Dopaminergic agonists are effective in the shrinkage of prolactin-secreting pituitary tumor and are preferred in some patients. However, pituitary radiotherapy may enable the long-term removal of prolactin-secreting tumor cells. Recent evidence suggests that prolactinoma is a heterogeneous disorder with complicated and multifactorial etiology and pathogenesis. Apparently, a thorough understanding of prolactinoma tumorigenesis would be important. To facilitate investigations on tumorigenesis of prolactinoma, animal models for prolactinomas have been developed. These models have expedited our progress in the recent years. Many researchers consider the F(344) rat to be the most sensitive strain of rats to estrogen (E(2))-induced prolactinoma formation. Nonetheless, E(2) treatment for 60 days also induces the formation of pituitary prolactin-secreting adenoma in male Sprague-Dawley (SD) rats. Evidently, the SD rat is also a good animal for prolactinoma investigations. Following E(2) implantation, prolactinomas developed in the eutopic adenohypophysis in situ and/or ectopic pituitary grafted under the renal capsule in SD rats. These observations favor the hypothesis that prolactinoma growth is the result of pathological changes in the adenohypophysis and/or hypothalamus. In the latter case, abnormal release of hypothalamic dopamine, GABA, or brain-gut peptides (such as cholecystokinin, vasoactive intestinal polypeptide, galanin, angiotensin, opioid peptide, gastrin, gastrin-releasing peptide, pancreatic polypeptide, and adrenocorticotropic hormone) results in some of the pathological changes that may lead to hyperprolactinemia and/or prolactinoma development. Dysregulation of prolactin synthesis and secretion may be the result of prolactin gene modulation. In E(2)-induced rat prolactinomas, prolactin mRNA contents and the expression of some proto-oncogenes, e.g. c-myc and c-ras, TGFalpha and TGFbeta1 mRNA were significantly changed. The above findings are consistent with results in human prolactinoma development. In addition, in rats abnormal expression of the prolactin gene was correlated with hypomethylated status of CpG sites in exons 1, 2 and 4 of the prolactin gene, as well as the increase in hypersensitive sites to DNase 1 in the encoding region of the prolactin gene. In E(2)-treated rats, a point mutation with a base substitution from cytidine (C) to adenine (A) was found at the -36-bp site of the proximal promoter of the prolactin gene in eutopic pituitary prolactinomas, but no change was observed in the same sequence of the prolactin gene in ectopic prolactinoma. The association of a base substitution with the hyperexpression of the prolactin gene in eutopic prolactinomas suggests that different mechanisms may mediate the formation of eutopic and ectopic prolactin-secreting tumors. Melatonin decreases the expression of the prolactin gene in vitro suggesting that this pineal hormone may be a potential anticarcinogen in vivo. It has also been shown that MT(2) (Mel(1b)) melatonin receptors are expressed in anterior pituitary cells. The use of melatonin as a preventive or therapeutic drug for prolactinomas should be further investigated. In summary, improved knowledge on tumorigenesis of prolactinomas, especially in the rat model, was noted. These E(2)-induced rat prolactinoma models would facilitate future investigations, and expected results shall be fruitful and exciting for the development of future drug designs for the prevention and/or treatment of prolactin-secreting pituitary tumors.     

Transforming growth factor-beta and activin inhibit basal secretion of prolactin in a pituitary monolayer culture system

Incubations of rat anterior pituitary cells with transforming growth factor (TGF)-beta 1 for 48 hr suppressed the secretion of basal prolactin (PRL) in a dose-dependent manner (ED50, 100 pg/ml). Activin, a gonadal hormone processing cysteine distribution similar to TGF beta, also suppressed basal PRL secretion, but it was less effective (ED50, 4 mg/ml). Treatment with TGF beta 1 significantly suppressed basal PRL secretion from the pituitary after 24 hr and up to 72 hr of incubation. TGF beta 1 also inhibited thyrotropin-releasing hormone-mediated PRL secretion and activin inhibited thyrotropin-releasing hormone-mediated PRL secretion slightly, but significantly. In addition, we also measured the secretion of growth hormone by cultured pituitary cells treated with TGF beta 1 or activin for 24 to 72 hr. TGF beta 1 and activin showed an opposite effect on growth hormone secretion; TGF beta stimulated and activin inhibited basal secretion of growth hormone. These results suggest that TGF beta 1 is a potent inhibitor of basal secretion of PRL by the pituitary, and both TGF beta 1 and activin play a multifunctional role in basal secretion of pituitary hormones.     

Transforming growth factor-beta (TGF beta) inhibits TGF alpha expression in bovine anterior pituitary-derived cells.

Transforming growth factor-beta 1 (TGF beta 1) is a multifunctional regulator of cell growth and differentiation. We report here that TGF beta 1 decreased the proliferation of nontransformed bovine anterior pituitary-derived cells grown in culture. We have previously demonstrated that these cells express both TGF alpha and its receptor [the epidermal growth factor (EGF) receptor] and that expression can be stimulated by phorbol ester (TPA) and EGF. TGF beta 1 treatment over a 2-day period decreased the proliferation of pituitary cells. This decreased growth rate was accompanied by a decrease in the TGF alpha mRNA level. The effect of TGF beta 1 on TGF alpha mRNA down-regulation was both dose dependent (maximal effect observed at 1.0 ng/ml TGF beta 1) and time dependent (minimum of 2-day treatment with TGF beta 1 was required before a decrease in TGF alpha mRNA was observed). Studies on TGF alpha mRNA stability indicated that TGF beta 1 did not alter the TGF alpha mRNA half-life. Treatment of the TGF beta 1 down-regulated cells with EGF resulted in the stimulation of TGF alpha mRNA levels; thus, the TGF beta 1-treated cells remained responsive to EGF. The decreased proliferation in response to TGF beta 1 could be only partially reversed by simultaneous treatment of the cells with EGF (10(-9)M) and TGF beta 1 (3.0 ng/ml). Qualitatively, the TGF beta 1-induced reduction of TGF alpha mRNA content was independent of cell density. TGF beta 1 treatment of the anterior pituitary-derived cells also reduced the levels of c-myc and EGF receptor mRNA. These results represent the first demonstration of the down-regulation of TGF alpha synthesis by a polypeptide growth factor and suggest that TGF beta 1 may be a physiological regulator of TGF alpha production in vivo.     

褪黑素通过减弱催乳素基因增强子的突变抑制大鼠垂体催乳素瘤的增生

本工作旨在探讨褪黑素(melatonin,MLT)抑制17-β-雌二醇(17-β-estradiol,E2)诱发的Sprague-Dawley大鼠垂体催乳素(prolactin,PRL)瘤增生的分子机制。结果表明,每只大鼠每日定时皮下注射一定剂量的MLT(0.25、0.50mg)能显著抑制E2诱发的大鼠垂体PRL瘤的增生;偏低(0.05mg)或过高剂量(1.00、2.00mg)的MLT也抑制PRL瘤的增生,但无统计学意义。采用PCR和DNA直接测序显示,与正常垂体对照组比较,PRL瘤中PRL基因增强子出现五处突变,-1885bp位点由C突变为G,-1857~-1855由ACA替换为G,-1792~-1791插入G,-1383~-1382插入GGTGTGTG片段,-1265~-1250缺失GTGTGTGTGTGTGTGT片段。0.25mg/dMLT处理组,PRL瘤中的PRL基因增强子上述个别突变部位仍然存在(-1885由C突变为G),突变消失(-1792~-1791无插入G),大部分表现为突变减弱(-1856~-1855缺失AC,-1385~-1384缺失TG,-1250~-1253缺失GTGT)。采用荧光素酶报告基因检测PRL基因增强子活性显示,正常垂体、PRL瘤和0.25mg/dMLT处理的PRL瘤三组中,PRL基因增强子的活性分别为(13448.17±3012.74)、(161831.67±60996.01)和(10212.17±2634.71)OD单位。PRL瘤组增强子活性较正常垂体升高11倍(P<0.001),MLT处理组增强子活性较PRL瘤组降低93.69%(P<0.001)。上述三组PRL基因增强子空间结构的分析表明,PRL基因增强子DNA的曲折程度为PRL瘤组>MLT处理组>正常垂体。以上结果证实,MLT抑制大鼠垂体PRL瘤增生的重要分子机制之一可能是减弱PRL基因增强子的突变,也提示MLT可减弱PRL基因增强子的突变,从而下调PRL基因的高表达,可能与降低DNA的曲折程度有关。     

转录因子E2F-1与垂体肿瘤转化基因（PTTG）在大鼠PRL瘤中的表达

目的通过检测垂体肿瘤转化基因（PTTG）与腺病毒E2启动子结合因子1（E2F-1）在大鼠催乳素（PRL）瘤中的表达来探讨两者在PRL瘤发生发展过程中的作用。方法 40只大鼠随机分为两组：实验组（E组,n=20）：皮下植入17β-雌二醇的方法诱发大鼠PRL瘤;对照组（C组,n=20）：皮下植入空白硅胶管。雌激素诱导10周后处死大鼠,心脏穿刺取血,4%多聚甲醛体内灌流取出脑垂体,称重,ELISA方法检测两组大鼠血清PRL水平,垂体组织行病理组织学观察,免疫组化SP方法检测两组大鼠垂体组织中PTTG蛋白质、E2F-1蛋白质的表达。结果雌二醇作用10周后,据垂体重量、垂体组织学变化和血清PRL水平证实PRL瘤诱导成功。PRL瘤组中,PTTG蛋白质、E2F-1蛋白质均明显高于对照组,差异具有统计学意义（P〈0.01）;且PTTG蛋白质和E2F-1蛋白质的表达呈明显正相关（γ=0.764,P〈0.01）。结论 PTTG与E2F-1在大鼠PRL瘤中共同过度表达,参与了大鼠PRL瘤的发生发展。     

Cloning of a growth arrest-specific and transforming growth factor beta-regulated gene, TI 1, from an epithelial cell line.

By cDNA cloning and differential screening, five genes that are regulated by transforming growth factor beta (TGF beta) in mink lung epithelial cells were identified. A novel membrane protein gene, TI 1, was identified which was downregulated by TGF beta and serum in quiescent cells. In actively growing cells, the TI 1 gene is rapidly and transiently induced by TGF beta, and it is overexpressed in the presence of protein synthesis inhibitors. It appears to be related to a family of transmembrane glycoproteins that are expressed on lymphocytes and tumor cells. The four other genes were all induced by TGF beta and correspond to the genes of collagen alpha type I, fibronectin, plasminogen activator inhibitor 1, and the monocyte chemotactic cell-activating factor (JE gene) previously shown to be TGF beta regulated.